Celgene Corporation's study results of romidepsin in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of patients with peripheral T-cell lymphoma showed 51% of patients achieved a complete response, according to a Celgene press release.
Celgene Corporation’s study results of romidepsin (Istodax) in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of patients with peripheral T-cell lymphoma (PTCL) showed 51% of patients achieved a complete response, according to a Celgene press release.
Thirty-seven patients took Istodax at varying dosages, plus CHOP, according to Celgene. Two patients were excluded from the efficacy analysis after they experienced myocardial infarction, and a third individual took only CHOP after experiencing acute cardiac failure.
Of the remaining patients, 51% achieved a complete response, 17% achieved a partial response, and 26% saw progressive disease.
The most common hematologic side effects reported were neutropenia, thrombocytopenia, and anemia, while the most common nonhematologic side effects included febrile neutropenia, general physical health deterioration, hypophosphatemia, and vomiting, Celgene noted.
“Based on this study, the combination of romidepsin and CHOP shows potential for the treatment of patients with PTCL, and supports further study through the phase III comparison of RO-CHOP and CHOP alone in this area of disease,” said Bertrand Coiffier, MD, PhD, lead investigator of the study, in a press release.
Istodax in combination with CHOP has not been approved for any indication in any country, Celgene noted.